Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.34 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1614023 | 0.85 | MAP3K14 (0.37) | MAP3K14DHFRHSP90B1TRAP1PDE4B | |
| SCHEMBL12714084 | 0.82 | AKT1 (0.41) | MAP3K14PIK3CADHFRPDE4BHRH4 | |
| SCHEMBL12714107 | 0.81 | AKT1 (0.36) | MAP3K14PIK3CADHFRHSP90B1TRAP1 | |
| SCHEMBL1613818 | 0.81 | AKT1 (0.36) | MAP3K14PIK3CADHFRHSP90B1TRAP1 | |
| SCHEMBL1613278 | 0.81 | MAP3K14 (0.32) | MAP3K14HSP90B1TRAP1 | |
| SCHEMBL1613397 | 0.81 | PIK3CA (0.47) | PIK3CAPIK3CDPIK3CBPDE4B | |
| SCHEMBL12743773 | 0.80 | PDE2A (0.35) | PIK3CAPIK3CDPIK3CBPIK3CGPDE4B | |
| SCHEMBL1612018 | 0.78 | MAP3K14 (0.60) | MAP3K14DHFRHSP90B1TRAP1HRH4 | |
| SCHEMBL1613669 | 0.76 | HRH4 (0.33) | MAP3K14PIK3CAPIK3CDPIK3CGHRH4 | |
| SCHEMBL1613018 | 0.76 | PAK4 (0.43) | MAP3K14BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2315751-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | Amgen Inc. (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2011-04-14 | — | — | US | disclosed |
| WO-2009158011-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009158011-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | NFKBIA, MAP3K1, MAP3K2 | MAP3K14 17/4885PIK3CA 334/4885PIK3CD 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.